Hikma Pharmaceuticals

-4.0%

1. Regulatory Risk: The company is subject to regulations by various health authorities worldwide in relation to the manufacturing, marketing and selling of its products. Any changes or delays in obtaining regulatory approval may have a negative effect on the company’s financial performance.

2. Drug Development Risk: The company is heavily dependent on the development of new drugs and products. If these products fail to reach the market, then Hikma’s products will become less competitive and its revenue will suffer.

3. Price Risk: The company’s product pricing is subject to various conditions including competition, government regulation, market conditions, and economic conditions. Changes in these conditions could result in decreased pricing of its products, resulting in decreased revenue.

4. Currency Risk: A large portion of Hikma’s revenue comes from outside the USA. Changes in foreign currency exchange rates can significantly impact its revenues.

5. Political Risk: The company is subject to political and economic uncertainty in its various international markets, which could negatively affect its revenue.

6. Competition Risk: The industry is highly competitive and Hikma faces numerous highly experienced and well-funded competitors. If Hikma is unable to compete effectively, its revenues could suffer.